Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. (NYSE: A) is a global company in analytical and clinical laboratory technologies, and its news flow reflects activity across life sciences, diagnostics, and applied markets. Company announcements highlight how Agilent’s instruments, software, services, and expertise are used to help customers bring great science to life, as well as how it manages its financial performance and corporate governance.
On this page, readers can follow Agilent news related to earnings results, product introductions, regulatory-focused solutions, capital allocation, and investor events. Recent releases include quarterly and full-year financial results, with details on revenue, net income, and segment performance for the Life Sciences and Diagnostics Markets Group, the Agilent CrossLab Group, and the Applied Markets Group. These updates often include management commentary on business conditions and outlook.
Agilent’s news also covers product and technology developments. For example, the company has announced 21 CFR Part 11 compliance software for the xCELLigence RTCA eSight system, designed to support use in GMP-regulated manufacturing and quality control environments by adding secure user authentication, electronic signatures, and audit trails. Another announcement introduced Agilent Altura Ultra Inert HPLC Columns, described as high performance liquid chromatography columns suited for biotherapeutics applications such as peptide GLP-1 and oligonucleotide therapeutic development and quality control.
Investors and analysts can also find updates on capital markets activities, such as cash dividend declarations on Agilent’s common stock, and notices of participation in healthcare and investor conferences. Governance-related news, including leadership transitions and executive appointments, is communicated through press releases and related SEC filings. Bookmarking this page allows users to review Agilent’s ongoing communications about its operations, technologies, financial performance, and corporate developments in one place.
Contractor Connection (NYSE:A) announced a strategic partnership with Helixco to integrate Helixco’s time-and-materials validation platform into Contractor Connection’s commercial managed repair program. The partnership aims to add real-time transparency, standardized workflows, auditable documentation and improved billing accuracy across commercial repair projects.
The collaboration pairs Helixco’s validation technology with Contractor Connection’s credentialed contractor network to support consistency, accountability and more predictable commercial repair outcomes for carrier partners and contractors.
TORM plc (NASDAQ: TRMD / TRMD A) increased its share capital by 106,468 A-shares following exercise of Restricted Share Units (RSUs), corresponding to a nominal value of USD 1,064.68. A total of 34,880 shares were subscribed at DKK 131.80 and 71,588 at DKK 148.70.
The new ordinary A-shares carry voting and dividend rights as of issuance, are negotiable instruments, and are expected to be listed on Nasdaq Copenhagen as soon as possible. Transfer restrictions may apply in some jurisdictions, including U.S. securities law. After the increase, share capital totals USD 1,019,306.41 divided into 101,930,641 A-shares.
Agilent (NYSE: A) launched Agilent Advanced Therapeutics, a unified CDMO solution integrating BIOVECTRA (Canada) and Nucleic Acid Solutions (Colorado) to provide end-to-end development and manufacturing across discovery, process development, and clinical- and commercial-scale production.
The CDMO portfolio includes oligonucleotides, microbial fermentation, complex and synthetic chemistry, bioreagents, highly potent APIs, and cell line development, intended to streamline customer access to scalable, customizable manufacturing under a single partner.
TORM plc (NASDAQ: TRMD, TRMD A) announced on March 9, 2026 that Oaktree Capital Group Holdings GP, LLC notified the company that OCM Njord Holdings S.à r.l. holds 23,839,575 shares, representing 23.39% of TORM's total share capital and voting rights.
The disclosure was made under section 30 of the Danish Capital Markets Act and names the investor and the exact stake size.
Agilent (NYSE: A) has agreed to acquire Biocare Medical for $950 million in an all-cash transaction, adding a complementary portfolio of IHC, ISH and FISH antibodies, reagents and instruments.
Biocare generated over $90 million revenue in 2025, posted annual double-digit revenue and profit growth since 2021, and the deal is expected to be accretive to Agilent’s top-line growth, margin profile and non-instrument revenue mix in Year 1, with EPS accretion ~12 months after close. Closing is subject to regulatory approvals and expected by Agilent’s Q4 FY2026.
TORM plc (A) has issued formal notice and full proposals for its Annual General Meeting to be held at noon London time on Wednesday, 15 April 2026. The notice details the business to be proposed at the AGM and provides investor contact names and phone numbers for queries.
TORM plc (Nasdaq: A) has adopted a long-term incentive program granting Restricted Share Units (RSUs) to employees and Executive Director Jacob Meldgaard. For 2025, 1,356,087 RSUs will be granted and 255,200 RSUs to Jacob Meldgaard, vesting over three years from 01 January 2027.
Each RSU may be exercised for one TORM A-share at an exercise price of DKK 167.14; theoretical market value of the allocation is USD 10.9m. P&L impact is forecast at USD 6.2m (2026), 3.3m (2027) and 1.4m (2028).
TORM (A) reported full-year 2025 results with TCE USD 910m, adjusted EBITDA USD 578m and net profit USD 286m. Return on invested capital fell to 11.5% from 24.3% in 2024. The Board approved a Q4 dividend of USD 0.70 per share payable 25 March 2026. For 2026 TORM expects TCE USD 850–1,250m and EBITDA USD 500–900m, with 23% of 2026 earning days covered as of 17 February 2026.
Fleet activity included nine second-hand acquisitions, purchase options exercised on 14 leaseback vessels, and a year-end fleet of 93 vessels.
Agilent (NYSE: A) reported Q1 FY2026 revenue of $1.80 billion, up 7.0% reported and 4.4% core year-over-year, with GAAP EPS of $1.07 and non-GAAP EPS of $1.36. The company raised FY26 revenue guidance to $7.3–$7.5 billion and increased non-GAAP EPS range to $5.90–$6.04.
Segments: LDG revenue $679M (16.0% margin), ACG $758M (31.6% margin), AMG $361M (25.8% margin). Q2 revenue guide is $1.79–$1.82 billion; Q2 non-GAAP EPS $1.39–$1.42. Management cited weather headwinds but reaffirmed core growth and margin expansion.
Agilent (NYSE: A) will participate in TD Cowen’s 46th Annual Health Care Conference with a fireside chat featuring CFO Adam Elinoff and Head of Investor Relations Tejas Savant on March 3, 2026, 11:10–11:40 a.m. EST in Boston.
A live audio webcast and replay will be available on Agilent’s Investor Relations website. Agilent reported $6.95 billion revenue for fiscal 2025 and employs approximately 18,000 people worldwide.